SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode, a leader in molecular diagnostics panel testing, is excited to announce a significant enhancement to its BioCode ® Gastrointestinal Pathogen ...
Germantown, Maryland, and Venlo, the Netherlands, June 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Gastrointestinal ...
BEVERLY, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc. (LXXGF), (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative ...
Background. Molecular syndromic diagnostic panels can enhance pathogen identification in the approximately 2–4 billion episodes of acute gastroenteritis that occur annually worldwide. However, the ...
GERMANTOWN, Md., & VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory clearance of the first in a series of QIAstat-Dx ...
The burden of infectious diarrhoea remains a significant global health challenge, compounded by the diverse array of gastrointestinal pathogens including bacteria, viruses and parasites. Advances in ...
New Panther Fusion Gastrointestinal Bacterial and Expanded Bacterial Assays deliver tailored, actionable diagnostic results to support fast and informed patient care A variety of complex factors, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback